Changes in Attentional Control After a Focal Seizure. (ATTENTIONEPIF)

April 22, 2026 updated by: University Hospital, Lille
Epilepsy is frequently associated with cognitive and attentional disorders. Several studies have pointed out that there are modifications of brain activity in resting state during peri-ictal period in EEG and functional MRI. However, to date, no study has assessed the changes in attentional control after a seizure. The investigators hypothesize that a localized discharge is associated with a disorganization of the networks engaged in attentional control. In this regard, the investigators propose a prospective longitudinal study assessing the changes in attentional control after a focal seizure.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Administration of the subtest of divided attention of the Test of Attentional Performance (TAP), recording of the event related potentiels N200 and P300, measure of the variation of power in several frequency bands (theta, alpha and beta) and measure of the high-resolution EEG connectivity during an attentional task at several time-points : a first time during interictal period (no seizure for more than 24 hours) and 1, 3, 6 and 24 hours after a focal seizure.

Description

Inclusion Criteria:

  • Age superior to 18 and under 80
  • Focal epilepsy with indication to pre-surgery work-up and 5 days programmed hospitalization dedicated to this work-up
  • Normal global cognitive performance (standard progressive Raven matrices score > 5th percentile)
  • Be affiliated to the social security system
  • Have signed an informed consent

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Not able to give consent (Article 1121-8 of the CSP)
  • Vulnerable person
  • Being deprived of liberty by judicial or administrative decision (Article L 1121-6 of the CSP)
  • Guardianship
  • Have a high probability of not respecting the protocol or of abandoning the study
  • Absence of any epileptic seizure recorded during the hospitalization
  • Recurrent seizures preventing the recording of at least 24 hours without any seizure following a seizure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subtest of divided attention of the Test of Attentional Performance (TAP)
Time Frame: 24 hours
A first time during interictal period (no seizure for more than 24 hours) (this first measure will be repeated every day until a seizure is recorded) and 1, 3, 6 and 24 hours after a focal seizure.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
N200 amplitude and latency
Time Frame: 24 hours
A first time during interictal period (no seizure for more than 24 hours) (this first measure will be repeated every days until a seizure is recorded) and 1, 3, 6 and 24 hours after a focal seizure.
24 hours
Strength of EEG functionnal connectivity during an attentional task (global and regional)
Time Frame: 24 hours
A first time during interictal period (no seizure for more than 24 hours) (this first measure will be repeated every days until a seizure is recorded) and 1, 3, 6 and 24 hours after a focal seizure.
24 hours
Variation of power in several frequency bands (theta, alpha and beta) during an attentional task.
Time Frame: 24 hours
A first time during interictal period (no seizure for more than 24 hours) (this first measure will be repeated every day until a seizure is recorded) and 1, 3, 6 and 24 hours after a focal seizure.
24 hours
Magnetic resonance imaging functional connectivity.
Time Frame: up to 5 days
up to 5 days
Differences in N200 and P300 amplitude and latency recorded between different subgroups according to the epileptic focus.
Time Frame: 24 hours
A first time during interictal period (no seizure for more than 24 hours) (this first measure will be repeated every day until a seizure is recorded) and 1, 3, 6 and 24 hours after a focal seizure.
24 hours
P300 amplitude and latency
Time Frame: 24 hours
A first time during interictal period (no seizure for more than 24 hours) (this first measure will be repeated every days until a seizure is recorded) and 1, 3, 6 and 24 hours after a focal seizure.
24 hours
Differences in strength of EEG functional connectivity during an attentional task recorded between different subgroups according to the epileptic focus.
Time Frame: 24 hours
24 hours
Differences in variation of power in several frequency bands (theta, alpha and beta) during an attentional task recorded between different subgroups according to the epileptic focus.
Time Frame: 24 hours
24 hours
Differences in magnetic resonance imaging functional connectivity recorded between different subgroups according to the epileptic focus.
Time Frame: 24 hours
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 4, 2024

Primary Completion (Estimated)

March 9, 2027

Study Completion (Estimated)

March 9, 2027

Study Registration Dates

First Submitted

May 21, 2024

First Submitted That Met QC Criteria

June 13, 2024

First Posted (Actual)

June 20, 2024

Study Record Updates

Last Update Posted (Actual)

April 27, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022_0762

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Temporal Lobe Epilepsy

Clinical Trials on All included subjects

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe